Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770439 | 0.92 | HRH3 (0.52) | HRH3SMN1; SMN2RAB9AMAPTTRPV1 | |
| SCHEMBL4768082 | 0.91 | HRH3 (0.51) | HRH3SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL4771974 | 0.90 | CREBBP (0.58) | HRH3SMN1; SMN2RAB9ACREBBPROCK2 | |
| SCHEMBL4767429 | 0.89 | RAB9A (0.55) | HRH3SMN1; SMN2RAB9AMAPTKDM4E | |
| SCHEMBL4772436 | 0.87 | HRH3 (0.52) | HRH3SMN1; SMN2RAB9AMAPTCREBBP | |
| SCHEMBL4767859 | 0.85 | RORC (0.47) | HRH3SMN1; SMN2RAB9AMAPTROCK2 | |
| SCHEMBL4767935 | 0.84 | ABL1 (0.50) | HRH3SMN1; SMN2RAB9ACREBBPROCK2 | |
| SCHEMBL4768438 | 0.84 | HRH3 (0.48) | HRH3SMN1; SMN2RAB9AMAPTROCK2 | |
| SCHEMBL4774583 | 0.84 | HRH3 (0.57) | HRH3SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL4768232 | 0.83 | RAB9A (0.50) | HRH3SMN1; SMN2RAB9AMAPTCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | HRH3 1/4885SMN1; SMN2 2487/4885RAB9A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.